M. Laruelle et P. Abi-dargham, Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies, J PSYCHOPH, 13(4), 1999, pp. 358-371
Abnormalities of dopamine function in schizophrenia are suggested by the co
mmon antidopaminergic properties of antipsychotic medications. However, dir
ect evidence of a hyperdopaminergic state in schizophrenia has been difficu
lt to demonstrate, given the difficulty of measuring dopamine transmission
in the living human. brain. This situation is rapidly changing. Recent deve
lopments in positron emission tomography and single-photon emission tomogra
phic techniques enabled measurement of acute fluctuation of synaptic dopami
ne in. the vicinity of D-2 receptors. Using this technique, we, and others,
measured the increase in dopamine transmission following acute amphetamine
challenge in untreated patients with schizophrenia and matched healthy sub
jects. Following a brief overview of these new brain imaging techniques, th
e main results derived with this method in patients with schizophrenia are
described: (1) amphetamine-induced dopamine release is elevated in patients
with schizophrenia, supporting the idea that schizophrenia is associated w
ith dysregulation of dopamine transmission; (2) following amphetamine, hype
ractivity of dopamine transmission is associated with activation of psychot
ic symptomatology; (3) this dysregulation of dopamine release is not a long
-term consequence of previous neuroleptic treatment, and is detected in nev
er-medicated patients experiencing a first episode of the illness; and (4)
in contrast, this exaggerated response of the dopamine system to amphetamin
e exposure is not detected in patients studied during a period of illness s
tabilization, suggesting that the hyperdopaminergic state associated with s
chizophrenia fluctuates over time. In conclusion, a hyperdopaminergic state
might be present in schizophrenia during the initial episode and subsequen
t relapses, but not during periods of remission. This finding has important
consequences for the development of new treatment, strategies for the remi
ssion phase.